ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

An Overview of a Study of bb2121 in Multiple Myeloma

Sundar Jagannath, MDDS
Published Online:2:14 PM, Fri June 30, 2017

Sundar Jagannath, MDDS, professor, Medicine, Hematology, and Medical Oncology, Mount Sinai Hospital, discusses a first in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.